What is the BridgeBio Pharma Inc (BBIO) price today?

The price of BridgeBio Pharma Inc (BBIO) today is $74.48. This value reflects the latest market rate available on Pluang. Check the asset page for additional details such as 24-hour change, market trends, and trading volume.

What are the trading hours of US Stocks?

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.

Do I get a dividend from investing in US Stocks?

Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.

What is the fee for each transaction?

Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/Explore/US Market Price/Stocks/BBIO

Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today

Overview Financials Technicals Analysis Corp Action About

24H

YTD

Aura AI Summary

BridgeBio Pharma (BBIO) trades at $74.46, up 1.61% on the day, with a bearish technical signal but strong analyst support. Revenue grew to $222M in 2024 and $502M in 2025, yet the company remains unprofitable with a net margin of -144.39%. Recent news highlights pipeline progress, including NDA submissions and positive trial data for genetic disease treatments, driving investor optimism despite cash burn from operations.

The outlook hinges on pipeline execution and regulatory approvals, with a consensus price target of $97.70 implying 31% upside. Key risks include intense competition, high debt of $1.72B, and persistent losses. Institutional sentiment is bullish, but profitability challenges and cash flow negativity warrant caution for near-term investors.

Read full analysis

Key Stats

Market Cap
$14.20B
Sector
Health
3M Drawdown
-19.43%
Enterprise Value
$15.48B
Dividend Yield
-
Trading Activity
47% Buy | 53% Sell
Typical Hold Time
57 days

$74.48

52W Low: $32.26

28 May 2025

52W High: $79.91

22 Jan 2026

BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $14.20B, with an enterprise value of $15.48B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $32.26 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -19.43%, reflecting recent price volatility. On average, investors hold BridgeBio Pharma Inc for approximately 57 days, indicating typical investor behavior on the platform.

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Technical Indicators

Overall Summary

Bearish (16)Neutral (2)Bullish (9)

News

Benzinga2 mon ago

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

Benzinga4 mon ago

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Globe Newswire6 mon ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Globe Newswire6 mon ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Globe Newswire6 mon ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

People also bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

Market Cap
$14.20B
Sector
Health
3M Drawdown
-19.43%
Enterprise Value
$15.48B
Dividend Yield
-
Trading Activity
47% Buy | 53% Sell
Typical Hold Time
57 days

$74.48

52W Low: $32.26

28 May 2025

52W High: $79.91

22 Jan 2026

Let’s invest in this asset by signing up or download!

Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today

Aura AI Summary

Key Stats

About BridgeBio Pharma Inc

People also bought

Key Stats

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store